tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

ESALF Stock Latest News

Eisai Advances Early-Stage E2086 Study, Supporting Long-Term Pipeline Value
Company AnnouncementsEisai Advances Early-Stage E2086 Study, Supporting Long-Term Pipeline Value
13d ago
ESALF
Eisai’s E7090 Trial Update: A Targeted Cancer Bet With Growing Investor Relevance
PremiumCompany Announcements
Eisai’s E7090 Trial Update: A Targeted Cancer Bet With Growing Investor Relevance
16d ago
ESALF
ESALF Earnings this Week: How Will it Perform?
PremiumPre-Earnings
ESALF Earnings this Week: How Will it Perform?
1M ago
Eisai’s MORAb-202 Trial: A Promising Step in Cancer Treatment
PremiumCompany Announcements
Eisai’s MORAb-202 Trial: A Promising Step in Cancer Treatment
5M ago
ESALF
Eisai Co.’s Promising Study on E7386: A Game Changer in Cancer Treatment?
PremiumCompany Announcements
Eisai Co.’s Promising Study on E7386: A Game Changer in Cancer Treatment?
5M ago
ESALF
Eisai’s Pediatric Epilepsy Study: A Potential Game-Changer for Investors
PremiumCompany AnnouncementsEisai’s Pediatric Epilepsy Study: A Potential Game-Changer for Investors
5M ago
ESALF
Eisai Co.’s E1018 Study: A Potential Game-Changer in Malaria Treatment
Premium
Company Announcements
Eisai Co.’s E1018 Study: A Potential Game-Changer in Malaria Treatment
5M ago
ESALF
Eisai’s Tasfygo Study: A Closer Look at Safety in Biliary Tract Cancer
Premium
Company Announcements
Eisai’s Tasfygo Study: A Closer Look at Safety in Biliary Tract Cancer
5M ago
ESALF
Eisai Co. Evaluates Fycompa’s Safety in New Clinical Study
PremiumCompany Announcements
Eisai Co. Evaluates Fycompa’s Safety in New Clinical Study
5M ago
ESALF
Eisai Co.’s Tasurgratinib Study: Key Insights for Investors
PremiumCompany Announcements
Eisai Co.’s Tasurgratinib Study: Key Insights for Investors
5M ago
ESALF
Eisai’s Lecanemab Study: A Closer Look at Alzheimer’s Treatment Safety
PremiumCompany Announcements
Eisai’s Lecanemab Study: A Closer Look at Alzheimer’s Treatment Safety
5M ago
ESALF
Eisai’s Tazemetostat Study: A Key Update for Investors
PremiumCompany Announcements
Eisai’s Tazemetostat Study: A Key Update for Investors
5M ago
ESALF
Is ESALF a Buy, Before Earnings?
PremiumPre-EarningsIs ESALF a Buy, Before Earnings?
8M ago
Eisai Co.’s Phase 1 Study of E7389-LF: Potential Game-Changer in Cancer Treatment?
Premium
Company Announcements
Eisai Co.’s Phase 1 Study of E7389-LF: Potential Game-Changer in Cancer Treatment?
8M ago
ESALF
Eisai Co. Advances Cancer Treatment with E7389 Liposomal Study
Premium
Company Announcements
Eisai Co. Advances Cancer Treatment with E7389 Liposomal Study
8M ago
ESALF
Eisai’s Lemborexant Study: A New Hope for Insomnia Treatment?
PremiumCompany Announcements
Eisai’s Lemborexant Study: A New Hope for Insomnia Treatment?
9M ago
ESALF
Eisai’s Fycompa Safety Study: A Potential Game-Changer in Epilepsy Treatment
PremiumCompany Announcements
Eisai’s Fycompa Safety Study: A Potential Game-Changer in Epilepsy Treatment
9M ago
ESALF
Eisai Co’s Strategic Initiatives and Growth Justify Buy Rating Despite Leqembi Guidance Concerns
PremiumRatings
Eisai Co’s Strategic Initiatives and Growth Justify Buy Rating Despite Leqembi Guidance Concerns
10M ago
Eisai Co. Surpasses FY 2024 Expectations Amid Challenges
PremiumCompany Announcements
Eisai Co. Surpasses FY 2024 Expectations Amid Challenges
10M ago
Eisai Co. Reports Cautious Optimism Amid Q3 Growth
PremiumCompany AnnouncementsEisai Co. Reports Cautious Optimism Amid Q3 Growth
1y ago
ESALF Earnings this Week: How Will it Perform?
Premium
Pre-Earnings
ESALF Earnings this Week: How Will it Perform?
1y ago
Biogen (NASDAQ:BIIB) and Eisai Win FDA’s OK on Alzheimer’s Drug Dosing
Premium
Market News
Biogen (NASDAQ:BIIB) and Eisai Win FDA’s OK on Alzheimer’s Drug Dosing
1y ago
BIIB

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >